<DOC>
	<DOCNO>NCT00581945</DOCNO>
	<brief_summary>Was evaluate safety , tolerability efficacy multiple dos canakinumab ( ACZ885 ) vs. placebo administer via intravenous infusion ( IV ) , pulmonary function patient COPD</brief_summary>
	<brief_title>Safety Efficacy Multiple Doses Canakinumab ( ACZ885 ) Chronic Obstructive Pulmonary Disease ( COPD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male and/or female subject 4080 year ( inclusive ) age Subjects clinical diagnosis COPD Smokers Exsmokers smoke history least 20 pack year Postbronchodilator force expiratory volume 1 second ( FEV1 ) screen ≤ 50 % predict normal value Postbronchodilator FEV1/FVC ratio &lt; 70 % History least one treat exacerbation 24 month year prior screen CReactive Protein ( CRP ) ≥3.47 mg/L , Subjects concomitant lung disease significant concomitant medical condition would affect subject ' safety participate study , would expect impact result study Female subject must surgically sterilize least 6 month prior screen must use two form contraception , postmenopausal woman Able provide write informed consent prior study participation . Able communicate well investigator comply requirement study . COPD exacerbation ( ) require treatment within 4 week prior first dose History lung reduction surgery Any undiagnosed nodule chest xray Presence certain medical condition specify protocol Subjects require oral parenteral corticosteroid equivalent &gt; 10 mg/day &gt; 20 mg every day prednisone prednisolone Documented homozygous alpha1 antitrypsin deficiency . Participation clinical investigation within 4 week prior dose longer required local regulation . Donation loss 400 mL blood within 8 week prior dose . A past medical history clinically significant electrocardiogram ( ECG ) abnormalities family history prolong QTinterval syndrome . A known hypersensitivity drug similar study drug . History immunocompromise , include positive HIV test result . A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . History drug alcohol abuse within 12 month prior screen evidence abuse indicate laboratory assay conduct screening .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>